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Abstract
Respiratory complications due to coronavirus disease COVID-19 have claimed tens of thousands
of lives in 2020. Many cases of COVID-19 escalate from Severe Acute Respiratory Syndrome (SARS-
CoV-2) to viral pneumonia to acute respiratory distress syndrome (ARDS) to death. Extracorporeal
membranous oxygenation (ECMO) is a life-sustaining oxygenation and ventilation therapy that may
be used for patients with severe ARDS when mechanical ventilation is insucient to sustain life. While
early planning and surgical cannulation for ECMO can increase survival, clinicians report the lack of a
risk score hinders these eorts. In this work, we leverage machine learning techniques to develop the
PEER score, used to highlight critically ill patients with viral or unspecied pneumonia at high risk of
mortality or decompensation in a subpopulation eligible for ECMO. The PEER score is validated on two
large, publicly available critical care databases and predicts mortality at least as well as other existing
risk scores. Stratifying our cohorts into low-risk and high-risk groups, we nd that the high-risk group
also has a higher proportion of decompensation indicators such as vasopressor and ventilator use.
Finally, the PEER score is provided in the form of a nomogram for direct calculation of patient risk, and
can be used to highlight at-risk patients among critical care patients eligible for ECMO.
1 Introduction
Coronavirus disease COVID-19 has spread globally, resulting in millions of infections. Many cases of
COVID-19 progress from Severe Acute Respiratory Syndrome (SARS-CoV-2) to viral pneumonia to acute
respiratory distress syndrome (ARDS) to death. Extracorporeal membrane oxygenation (ECMO) can tem-
porarily sustain patients with severe ARDS to bridge periods of time when oxygenation via the lungs
cannot be achieved via mechanical ventilation. However, ECMO is expensive and applicable only for pa-
tients healthy enough to recover and return to a high functional status. While ECMO is more eective
when planned in advance [Combes et al., 2018], applicable risk scores remain unavailable [Liang et al.,
2020, American College of Cardiology, 2020].
This paper introduces the Viral or Unspecied Pneumonia ECMO-Eligible Risk Score, or PEER score
for short. This risk score focuses on a critical care population eligible for ECMO and uses measurements
acquired at the time of would-be planning—early in the critical care stay. While other pneumonia-based
risk scores exist [Fine et al., 1997, Marti et al., 2012, Charles et al., 2008, Lim et al., 2003a], our PEER score
specically addresses risks associated with viral or unspecied pneumonia in the critical care setting and
the cohort potentially eligible for ECMO. Inclusion of unspecied pneumonia broadens the population
studied, and is chosen because the infectious etiology of pneumonia often cannot be determined.
∗Equal contribution.
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Though limited by geographic availability, ECMO usage has increased 4-fold in the last decade [Ra-
manathan et al., 2020]. COVID-19 guidelines suggest ECMO as a late option in the escalation of care in
severe ARDS secondary to SARS-CoV-2 infection [Liang et al., 2020, Alhazzani et al., 2020]. However, early
evidence from epidemiological studies of coronavirus [Wang et al., 2020, Yang et al., 2020, Zhou et al., 2020]
has been insucient to establish ECMO’s utility. A pooled analysis of four studies [Henry, 2020] showed
mortality rates of 95% with the use of ECMO vs. 70% without, but the number of patients receiving ECMO
was small, and none of these studies were controlled nor did they specify indications for ECMO.
In this paper, to better understand the role of ECMO as a rescue for ventilation non-responsive, SARS-
CoV-2 ARDS, we study risk of death in ARDS among ECMO-eligible patients. Treatment guidelines for
ARDS suggest ECMO use in severe ARDS alongside other advanced ventilation strategies [Matthay et al.,
2020]. World Health Organization interim guidance also suggests ECMO for ARDS [World Health Orga-
nization et al., 2020], citing eectiveness in ARDS and mortality reductions in Middle East Respiratory
Syndrome (MERS). Despite these recommendations and the resources allocated to ECMO for these sit-
uations [Ramanathan et al., 2020], risk scores tailored to ECMO consideration are lacking. Our study
addresses this need by drawing from viral and source unidentied cases of pneumonia that escalate to
critical care admissions, guided by the intuition that ARDS associated with these pneumonia are expected
to better resemble COVID-19 ARDS than all-comer ARDS.
We develop and evaluate a risk score for critical care patients with viral or unspecied pneumonia and
who are eligible for ECMO. Our risk score is validated on two large, publicly available critical care databases
and predicts mortality at least as well as other existing risk scores. We stratify our cohorts into low-risk
and high-risk groups, and nd that the high-risk group also has a higher proportion of decompensation
indicators such as vasopressor and ventilator use. Finally, we provide the risk score in the form of a
nomogram for direct calculation of patient risk. We provide this risk score as an assistive tool to highlight
at-risk patients among critical care patients eligible for ECMO.
Related Work
There are a number of pneumonia [Lim et al., 2003b, Fine et al., 1997, Charles et al., 2008, Lim et al., 2003a,
Guo et al., 2019], COVID-19 [Gong et al., 2020b, Jiang et al., 2020, Gong et al., 2020a], hospitalization
mortality [Zimmerman et al., 2006], and ECMO risk scores [Schmidt et al., 2015], but none are focused
around the time of risk evaluation for ECMO candidacy. The pneumonia and COVID-19 risk scores are
assessed on populations with lower acuity, while APACHE is not focused on patients with respiratory
illness. Our risk score focuses at the stage of ECMO planning rather than among patients already receiving
ECMO.
Registry-based studies have also considered expected mortality variation in SARS-CoV-2 compared to
that of other viral infections, including MERS, H1N1 u, and seasonal u. One MERS-related ARDS study
of critically ill patients demonstrated a higher mortality rate than those in studies on COVID-related ARDS,
but may be attributed to more severely ill patients at enrollment [Arabi et al., 2017]. A similar study of
H1N1 reported lower mortality rates (12-17%), albeit considering a younger population with average age
of 40 [Aokage et al., 2015].
Physiologic concerns have also been raised about the use of ECMO for SARS-CoV-2. While ECMO
is primarily benecial for respiratory recovery, some argue that a spike in all-cause death but not ARDS-
related death could indicate a limited role of ECMO [Henry and Lippi, 2020]. In addition, COVID-associated
lymphopenia might be exacerbated by ECMO-induced lymphopenia which could mechanistically aect a
healthy immune response to infection. Inammatory cytokines and specically interleukin 6 elevation is
associated with COVID-19 mortality and rises with the use of ECMO [Henry, 2020, Bizzarro et al., 2011].
These expert voices do not argue for the avoidance of ECMO, but rather call for additional study.
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2 Data
The eICU Collaborative Research Database [Pollard et al., 2018] contains data for 200,859 admissions to in-
tensive care units (ICU) across multiple centers in the United States between 2014 and 2015. The MIMIC-III
clinical database [Johnson et al., 2016] consists of data from 46,476 patients who stayed in critical care units
of the Beth Israel Deaconess Medical Center between 2001 and 2012. Our analysis and model development
is done primarily using data derived from eICU, and externally validated on data derived from MIMIC-III.
Cohort Selection Data for the study cohort were extracted according to the inclusion and exclusion
criteria summarized in Figure 2.1. Our population of interest is patients with viral or otherwise unspec-
ied non-bacterial, non-fungal, non-parasitic, and non-genetic pneumonia. While there are no absolute
contraindications of ECMO, the therapy is reserved for patients likely to have functional recovery. Thus,
patients over 70 years old were excluded since they would not be good candidates for ECMO, and patients
under 18 were excluded because SARS-CoV-2 pneumonia progressing to hypoxic respiratory failure is ex-
ceedingly rare in this age group. Other relative contraindications to ECMO include stroke, intracranial
hemorrhage, disseminated intravascular coagulation, cancer, liver disease, renal failure, patients under-
going surgery, and congestive heart failure. Over the course of each patient’s hospital stay, the rst ICU
stay was analyzed. Patients who died or were discharged within the rst 48 hours of being admitted were
excluded to focus on the stage of critical care after initial entry when lower-risk oxygen supplementation
strategies (e.g., ventilation) are being performed, and, methodologically, to provide a richer set of features
for prediction. Table 1 summarizes demographics and outcomes of the cohorts.
Viral/	unspecified	
pneumonia	patients	
(n=17,390)
Included	(n=9,500)
Excluded	(n=7,890)
patients	over	70,	
under	18,	or	not	reported
Excluded	(n=2,882)
patients	with	surgery,	
stroke,	intracranial
hemorrhage,	cancer,	liver
disease,	renal	failure,
congestive	heart	failureIncluded	(n=6,618)
ICU	stays	from	
eICU	database	
(n=200,859)
Included	(n=6,088)
Excluded	(n=183,469)
non-pneumonia	and
bacterial	pneumonia	visits
Excluded	(n=530)
ICU	stays	after	the	
patient's	first	one
Cohort	used	in	study
(n=3,617)
Excluded	(n=2,471)
patients	discharged	
in	the	first	48	hours
(a) eICU cohort selection
Viral/	unspecified	
pneumonia	patients
(n=4,572)
Included	(n=2,348)
Excluded	(n=2,224)
patients	over	70	
or	age	not	reported
Excluded	(n=945)
patients	with	surgery,	
stroke,	intracranial
hemorrhage,	disseminated
intravascular	coagulation,	
liver	disease,	renal	failure,
congestive	heart	failure
Patients	with	ICU	stays
from	MIMIC	database	
(n=46,476)
Included	(n=1,403)
Non-pneumonia	and
bacterial	pneumonia	visits
excluded	(n=41,904)
Excluded	(n=436)
ICU	stays	after	the	
patient's	first	one	
and	patients	discharged	
in	the	first	48	hours
Included	(n=967)
Excluded	(n=30)
patients	under	18
Cohort	used	in	study
(n=937)
Viral/	unspecified	
pneumonia	patients
(n=4,572)
Included	(n=2,348)
Excluded	(n=2,224)
patients	over	70	
or	age	not	reported
Excluded	(n=945)
patients	with	surgery,	
stroke,	intracranial
hemorrhage,	disseminated
intravascular	coagulation,	
liver	disease,	renal	failure,
congestive	heart	failureIncluded	(n=1,403)
ICU	stays	from	
MIMIC	database	
(n=46,476)
Included	(n=967)
Non-pneumonia	and
bacterial	pneumonia	visits
excluded	(n=41,904)
Excluded	(n=436)
ICU	stays	after	the	
patient's	first	one	
and	patients	discharged	
in	the	first	48	hours
Cohort	used	in	study
(n=937)
Excluded	(n=30)
patients	under	18
(b) MIMIC-III cohort selection
Figure 2.1: Inclusion and exclusion criteria for cohorts extracted from eICU and MIMIC. The disseminated
intravascular coagulation exclusion criteria could not be reliably extracted from eICU due to missing data.
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Table 1: Characteristics and treatment of patients with viral or unspecied pneumonia in eICU and MIMIC-
III cohorts. Data are median (Q1-Q3) or count (% out of n).
Variable eICU (n = 3617) MIMIC (n = 937)
Demographics
Age, years 58.0 (48.0-64.0) 54.5 (44.1-62.7)
Age range, years
18-30 225 (6.2%) 83 (8.9%)
30-39 277 (7.7%) 94 (10.0%)
40-49 500 (13.8%) 159 (17.0%)
50-59 1064 (29.4%) 281 (30.0%)
60-70 1546 (42.7%) 320 (34.2%)
Gender
Male 1949 (53.9%) 542 (57.8%)
Female 1663 (46.0%) 395 (42.2%)
Physical exam ndings
Orientation
oriented 1121 (31.0%) 411 (43.9%)
confused 1287 (35.6%) 76 (8.1%)
Temperature (°C) 36.9 (36.6-37.3) 37.2 (36.6-37.7)
Heart rate (beats per minute) 89.0 (77.0-101.0) 90.0 (78.0-104.0)
Respiratory rate (breaths per minute) 20.0 (17.0-25.0) 20.0 (16.0-25.0)
Systolic blood pressure (mmHg) 120.0 (106.0-136.0) 118.0 (104.0-134.0)
Diastolic blood pressure (mmHg) 66.0 (57.0-76.0) 63.0 (54.0-72.0)
Mean arterial pressure (mmHg) 81.0 (72.0-93.0) 79.0 (71.0-90.0)
Glasgow Coma Scale 14.0 (10.0-15.0) 14.0 (9.0-15.0)
Laboratory ndings
Hemotology
Red blood cells (millions/µL) 3.5 (3.0-4.0) 3.4 (3.0-3.8)
White blood cells (thousands/µL) 11.0 (7.9-15.6) 11.0 (8.0-15.1)
Platelets (thousands/µL) 193.0 (136.0-261.0) 199.0 (128.8-276.0)
Hematocrit (%) 31.1 (27.2-35.6) 30.2 (27.0-33.6)
Red blood cell dist. width (%) 15.2 (14.0-16.8) 14.8 (13.8-16.4)
Mean corpuscular volume (fL) 90.4 (86.0-95.0) 89.0 (85.0-93.0)
Mean corpuscular hemoglobin/ MCH (pg) 29.7 (27.9-31.2) 30.2 (28.7-31.6)
MCH concentration (g/dL) 32.7 (31.7-33.6) 33.8 (32.8-34.8)
Neutrophils (%) 82.0 (73.3-89.0) 82.3 (73.8-88.5)
Lymphocytes (%) 8.4 (5.0-14.0) 9.5 (5.8-15.7)
Monocytes (%) 6.0 (3.7-8.6) 4.0 (2.7-5.9)
Eosinophils (%) 0.1 (0.0-1.0) 0.4 (0.0-1.2)
Basophils (%) 0.0 (0.0-0.3) 0.1 (0.0-0.3)
Band cells (%) 8.0 (3.0-17.0) 0.0 (0.0-5.0)
Chemistry
Sodium (mmol/L) 139.0 (136.0-142.0) 139.0 (136.0-142.0)
Potassium (mmol/L) 3.9 (3.6-4.3) 3.9 (3.6-4.3)
Chloride (mmol/L) 105.0 (101.0-109.0) 105.0 (101.0-109.0)
Bicarbonate (mmol/L) 25.0 (22.0-28.0) 26.0 (23.0-29.0)
Blood urea nitrogen (mg/dL) 19.0 (12.0-33.0) 17.0 (11.0-28.0)
Creatinine (mg/dL) 0.8 (0.6-1.4) 0.8 (0.6-1.3)
Glucose (mg/dL) 131.0 (105.0-165.0) 124.0 (104.5-151.5)
Aspartate aminotransferase (units/L) 30.0 (19.0-57.0) 37.0 (22.0-70.0)
Alanine aminotransferase (units/L) 27.0 (16.0-47.0) 28.0 (18.0-52.0)
Alkaline phosphatase (units/L) 84.0 (62.0-117.0) 85.0 (62.0-121.0)
C-reactive protein (mg/L) 19.6 (8.8-42.2) 35.9 (8.3-98.8)
Direct bilirubin (mg/L) 0.2 (0.1-0.5) 0.6 (0.2-2.2)
Total bilirubin (mg/L) 0.5 (0.3-0.8) 0.6 (0.4-1.1)
Total protein (g/dL) 6.0 (5.3-6.7) 6.1 (5.3-7.0)
Calcium (mg/dL) 8.2 (7.7-8.6) 8.2 (7.8-8.6)
Albumin (g/dL) 2.6 (2.2-3.1) 3.0 (2.6-3.5)
Troponin (ng/mL) 0.1 (0.0-0.2) 0.0 (0.0-0.3)
Coagulation
Prothrombin time (sec) 14.5 (12.7-16.7) 13.9 (13.0-15.3)
Partial thromboplastin time (sec) 33.0 (28.5-41.0) 30.2 (26.6-36.9)
Blood gas
pH 7.39 (7.33-7.43) 7.41 (7.36-7.45)
Partial pressure of oxygen (mmHg) 83.0 (68.0-111.0) 97.0 (73.5-127.5)
Arterial oxygen saturation (mmHg) 96.0 (94.0-99.0) 97.0 (95.0-98.0)
Outcomes
Deceased 270 (7.5%) 94 (10.0%)
Vasopressors administered 589 (16.3%) 389 (41.5%)
Ventilator used 1835 (50.7%) 758 (80.9%)
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Data Extraction The eICU and MIMIC cohorts were extracted using string matching on diagnosis codes
and subsequent clinician review of the descriptors (provided in Appendix A). Features were manually
merged from several tables into their corresponding elements based on a process of visualization, query,
and physician review. This involved harmonizing feature units (e.g. Farenheit to Celsius), removing im-
possible values (e.g. negative blood pressures), and merging redundant data elds (e.g., lling in the sum
of the individual Motor, Verbal, and Eye Opening Score elds for the Glasgow Coma Score Total when it
was missing). We provide additional feature and outcome extraction details in Appendix B.
All features were combined into a xed-length vector, using the most recent value prior to 48 hours
after ICU admission. Before imputation, approximately half of the features had missingness below 5%,
and 80% of the features had missingness below 30%, however several variables have high missingness
(Appendix C). Missing values were imputed using MissForest [Stekhoven and BÃĳhlmann, 2011] and our
model was not sensitive to MissForest imputation (Appendix F).
Features Features were extracted from demographics, comorbidities, vitals, physical exam ndings, and
laboratory ndings routinely collected in critical care settings. Numerical features were normalized, and
categorical features were converted into binary features (one less than the number of categories). The 52
features provided to the model are listed in Appendix B.
Outcomes Our primary outcome of interest is in-ICU mortality. Secondary outcomes indicating decom-
pensation include (1) vasopressor use and (2) mechanical ventilation use. For each outcome, we dene the
time to event as the time to rst outcome or censorship, where censorship corresponds to discharge from
the ICU. For details, see Appendix B.
3 Methods
Lasso-Cox To predict patients’ survival time, we use the Cox proportional hazards model [Cox, 1972]
with L1 regularization, referred to as Lasso-Cox [Simon et al., 2011]. We choose Lasso-Cox for its ease of
interpretation and calculation, owing to its selection of sparse models.∗ In particular, for a patient with
covariates x ∈ Rd, the predicted log hazard of the patient is β>x (higher log hazard is associated with
shorter survival time), where β ∈ Rd is the vector of Cox regression coecients that can be interpreted
as log hazard ratios. During model tting, L1 regularization λ
∑d
j=1 |βj | is used to encourage only a few
features to have nonzero β value, where λ > 0 is a user-specied hyperparameter.
Evaluation Metrics To evaluate model performance, we consider concordance and calibration. Concor-
dance (c-index) is a common measure of goodness-of-t in survival models [Harrell and et al., 1982], dened
as the fraction of pairs of subjects whose survival times are correctly ordered by a prediction algorithm,
among all pairs that can be ordered.
To compute concordance condence intervals we use 1000 bootstrapped replicates, each the size of the
dataset and sampled with replacement. Calibration is evaluated by plotting the Kaplan-Meier observed sur-
vival probability versus the predicted survival probability. Using the R package hdnom [Xiao et al., 2016],
we construct our calibration plots (Figure 4.2) with 1000 bootstrap resamplings for internal calibration,
using 5 groups and a prediction time of 3 days.
Experimental Setup We divided the eICU cohort into a training set (70% of the data, n=2537) and test
set (30%, n=1080). The eICU training set is used for model selection and analysis, whereas the eICU test
set and entirety of the MIMIC cohort are used for model evaluation. Throughout our analysis, we compare
∗We also tried the Cox model with elastic-net regularization (combined L1 and L2 regularization) but found little to no gain
in concordance.
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our risk score (PEER) to three pneumonia risk scores: CURB-65 [Lim et al., 2003b], PSI/PORT [Fine et al.,
1997], and SMART-COP [Charles et al., 2008]; and one COVID-19 risk score: GOQ [Gong et al., 2020b].
Model selection We select λ via 10-fold cross validation and grid search on the eICU training set to maxi-
mize concordance subject to sucient sparsity. We observe that λ = 0.01 gives the best trade-o between
concordance (0.73) and number of features selected (18), as a 0.01 increase in concordance corresponds
to 10 additional non-zero features. To check the stability of this hyperparameter choice, we imputed our
data using ten random seeds and ran 10-fold cross validation on the resulting datasets. Across all runs,
λ = 0.01 achieved concordance of approximately 0.73 and selected similar features and coecients. Addi-
tional details about grid search, the concordance and sparsity tradeo, and robust selection of coecients
can be found in Appendix D, Appendix Figure F.1, and Appendix Figure F.2.
Code for data extraction and all model results is available at https://github.com/hlzhou/peer-score.
4 Results
As explained in Section 3, model selection yielded a L1-regularized Cox model with λ = 0.01. The learned
hazard ratios, i.e. the PEER score, for normalized data are displayed in Table 2 and as a boxplot in Appendix
Figure E.1. For reference, Appendix E contains the standard deviation and mean of each feature in the
model. To assist with easy risk score calculation, we also provide a nomogram [Xiao et al., 2016] in Figure
4.1†.
Table 2: Hazard ratios for the Lasso-Cox model, i.e. the PEER score, excluding hazard ratios equal to 1
(since they do not contribute to the model). Hazards ratios (HR) and 95% condence intervals (CI) are
reported on normalized data.
Feature HR (95% CI)
Age (years) 1.22 (1.04 – 1.43)
Heart rate (beats per minute) 1.13 (0.984 – 1.3)
Systolic blood pressure (mmHg) 0.928 (0.755 – 1.14)
Diastolic blood pressure (mmHg) 0.996 (0.745 – 1.33)
Mean arterial pressure (mmHg) 0.926 (0.673 – 1.27)
Glasgow Coma Scale 0.93 (0.803 – 1.08)
White blood cells (thousands/µL) 0.984 (0.871 – 1.11)
Platelets (thousands/µL) 0.924 (0.79 – 1.08)
Red blood cell dist. width (%) 1.24 (1.08 – 1.43)
Neutrophils (%) 0.972 (0.853 – 1.11)
Blood urea nitrogen (mg/dL) 1.07 (0.937 – 1.23)
Aspartate aminotransferase (units/L) 1.12 (1.06 – 1.18)
Direct bilirubin (mg/L) 1.03 (0.935 – 1.13)
Albumin (g/dL) 0.954 (0.82 – 1.11)
Troponin (ng/mL) 1.06 (0.985 – 1.14)
Prothrombin time (sec) 1.05 (0.909 – 1.2)
pH 0.856 (0.75 – 0.977)
Arterial oxygen saturation (mmHg) 0.787 (0.723 – 0.856)
†To use this nomogram, look up a patient’s original (pre-normalization) values, match it to a number of points listed across
the top, and look up the sum of that patient’s points in the scale across the bottom.
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Table 3: Concordances of the PEER score, CURB-65, PSI/PORT, SMART-COP, and GOQ. Bootstrapping
with 1000 replicates was used to compute 95% condence intervals (in parentheses).
Score Train eICU Test eICU MIMIC
concordance concordance concordance
PEER (ours) 0.77 (0.72 - 0.81) 0.77 (0.69 - 0.83) 0.66 (0.57 - 0.74)
CURB-65 [Lim et al., 2003b] 0.66 (0.61 - 0.70) 0.62 (0.55 - 0.69) 0.59 (0.52 - 0.66)
PSI/PORT [Fine et al., 1997] 0.71 (0.66 - 0.76) 0.71 (0.63 - 0.78) 0.62 (0.55 - 0.69)
SMART-COP [Charles et al., 2008] 0.69 (0.64 - 0.73) 0.73 (0.67 - 0.80) 0.66 (0.59 - 0.72)
GOQ [Gong et al., 2020b] 0.67 (0.63 - 0.71) 0.62 (0.54 - 0.70) 0.58 (0.50 - 0.66)
To evaluate discriminative ability, we use concordance. On both the eICU and MIMIC datasets, our
Lasso-Cox model (which we name the PEER score) achieves concordance greater than or comparable to
that of existing risk scores (Table 3). On the eICU test set, the PEER score achieves the highest concordance
among the risk scores, 0.77, with the second highest, 0.73, attained by SMART-COP. On the MIMIC dataset,
PEER and SMART-COP again achieve the highest concordances, but concordance degrades to 0.66 for both
scores. One possible reason for this degradation is that arterial oxygen saturation (SaO2) is a signicant
feature and only 1.5% of these values are missing in eICU, but in MIMIC 72.6% of these values are missing
(Appendix C).
From the PEER score calibration curves (Figure 4.2), we see one high risk group separate from the
other low risk groups. While predicted survival probability of the high risk group is overestimated in the
training set, it is estimated within condence intervals in both test sets.
(a) Train eICU (b) Test eICU (c) MIMIC
Figure 4.2: Calibration plots with 95% condence intervals on train eICU, test eICU, and test MIMIC.
To compare low-risk and high-risk populations (as dened by our model), we set a threshold at the
90th percentile of the predicted risk value from the training set. We nd that over a 7 day time pe-
riod, the Kaplan-Meier survival curves for the high and low risk subpopulations are clearly distinct Fig-
ure 4.3) [Davidson-Pilon et al., 2020]. At 7 days, the high risk and low risk groups in the eICU test set have
survival proportions 0.68 and 0.95, respectively. The gap is smaller in MIMIC with survival probabilities
of 0.75 and 0.95, respectively. In each case, the dierence in survival is larger for the PEER score than for
other risk scores (Appendix Figure G.1, with stratication details in Appendix G).
In addition to mortality, decompensation can be indicated by vasopressor and ventilator use. As ex-
pected, vasopressors and ventilators are more commonly used in the high risk group (Figure 4.4).
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Figure 4.1: Nomogram for manual calculation of the PEER score.
Figure 4.3: Kaplan-Meier survival curves of high vs. low risk groups in train eICU, test eICU, and MIMIC.
Shaded regions are the 95% condence intervals.
(a) vasopressor (b) ventilator
Figure 4.4: Proportion of high and low risk patients who received vasopressors or ventilators. High and
low risk groups are derived from the PEER score.
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5 Discussion
Our PEER score achieves greater or comparable concordance to baselines on the eICU (in-domain) and
MIMIC (out-of-domain) test sets. The Lasso-Cox model selects 18 features, making it easy to calculate. We
nd that lower SaO2, which is associated with poorer oxygenation status, is predictive of decompensation.
As expected, we also nd that old age is predictive of death. Red blood cell distribution width, associated
with expanded release of immature red blood cells as a response to insucient oxygen delivery to tissues,
is also a strong risk factor for death in patients with COVID-19 [Gong et al., 2020a]. Three variables (pH,
prothrombin time, and age) violate the proportional hazards assumption of the Cox model, and Lasso-Cox
models shrink coecients towards 0, so the hazard ratios themselves should be interpreted with caution.
Stratifying each cohort into low risk and high risk subpopulations based the PEER score, there is a clear
separation in their survival curves (Figure 4.3) across all three datasets, with the low risk group observing
a survival of 0.9 or greater after 7 days and the high risk group observing a survival of 0.75 or less. The
mortality-based high risk groups also are associated with our proximate indicators of decompensation:
vasopressor and ventilator use (Figure 4.4). Compared to the survival curves for low and high risk subpop-
ulations derived from other risk scores, the survival curves from the PEER score are the most distinctly
separated (Appendix G Figure G.1).
Calibration plots for the PEER score also show a high risk group clearly separated from the rest (Figure
4.2). While the survival probability of the high risk group is overestimated in the training set, it is within
error bars in the test set.
For ECMO allocation, practically, accurate ranking of risk, as measured by concordance, may be more
important than the probabilities predicted. While the PEER score outperformed other risk scores in the
eICU test set, there was a decline in performance on the MIMIC test set, and the performance of the PEER
score was comparable to that of SMART-COP. We also note that in MIMIC, arterial oxygen saturation
(SaO2) has 72.6% missingness yet is an important feature of the PEER score. In contrast, it has 1.5%
missingness in eICU. This demonstrates the importance of thinking critically about how our risk score,
which was trained on the eICU cohort and depends on 18 specic features, generalizes to the population
to which the score is being applied.
Limitations and Future Work Importantly our cohort is dened not by COVID-19 positive pneumonia
patients but instead by viral or unspecied pneumonia patients who are ECMO-eligible. While our risk
score demonstrates good discriminative ability and is interpretable, there are several additional decision-
making considerations beyond the scope of this paper. Clinicians interested in applying the risk score
to COVID-19 pneumonia should consider how representative this population is of their own. Because
ECMO is a constrained resource, there are also ethical questions about who should get treatment. This
risk score does not attempt to address these questions, but simply provides relevant information to those
making such decisions. More broadly, we hope to provide this risk score as a potential resource for future
SARS-like diseases that require ECMO consideration.
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A Cohort Selection
The cohort for model development and analysis on a held-out set was extracted from the eICU Collabora-
tive Research Database Version 2.0. A cohort was also extracted from MIMIC-III Version 1.4 for external
validation.
For both the eICU and MIMIC cohorts, viral or unspecied pneumonia patients were included by string
matching of International Classication of Disease (ICD 9) diagnosis code descriptions and subsequent
clinician review of these descriptors. Using the patient and demographics tables, patients over 70 or under
18 were excluded. Other relative contraindications to ECMO were likewise excluded by string matching
and clinician review of the resulting descriptors.
A.1 eICU Cohort
Below are the diagnosisstring’s used to select patients with viral or unspecied pneumonia.
'infectious diseases|chest/pulmonary infections|pneumonia|ventilator-associated',
'surgery|respiratory failure|ARDS|pulmonary etiology|pneumonia',
'infectious diseases|chest/pulmonary infections|pneumonia|community-acquired|viral',
'infectious diseases|chest/pulmonary infections|pneumonia',
'infectious diseases|chest/pulmonary infections|lung abscess|secondary to pneumonia',
'pulmonary|pulmonary infections|pneumonia|community-acquired|viral|respiratory syncytial',
'pulmonary|pulmonary infections|pneumonia|community-acquired',
'surgery|infections|pneumonia|hospital acquired (not ventilator-associated)',
'infectious diseases|chest/pulmonary infections|empyema|associated with pneumonia',
'pulmonary|pulmonary infections|pneumonia|hospital acquired (not ventilator-associated)',
'pulmonary|pulmonary infections|pneumonia|hospital acquired (not ventilator-associated)',
'infectious diseases|chest/pulmonary infections|pneumonia|opportunistic',
'surgery|respiratory failure|acute lung injury|pulmonary etiology|pneumonia',
'pulmonary|respiratory failure|acute lung injury|pulmonary etiology|pneumonia',
'infectious diseases|chest/pulmonary infections|pneumonia|community-acquired',
'surgery|infections|pneumonia',
'pulmonary|pulmonary infections|pneumonia|community-acquired|viral',
'infectious diseases|chest/pulmonary infections|pneumonia|hospital acquired
(not ventilator-associated)',
'pulmonary|respiratory failure|ARDS|pulmonary etiology|pneumonia',
'pulmonary|pulmonary infections|pneumonia|hospital acquired (not ventilator-associated)
|viral',
'transplant|s/p bone marrow transplant|idiopathic pneumonia syndrome - bone marrow
transplant',
'pulmonary|pulmonary infections|lung abscess|secondary to pneumonia',
'infectious diseases|chest/pulmonary infections|pneumonia|community-acquired|viral|
respiratory syncytial',
'pulmonary|pulmonary infections|pneumonia',
'pulmonary|pulmonary infections|pneumonia|ventilator-associated',
'pulmonary|pulmonary infections|pneumonia|opportunistic',
'surgery|infections|pneumonia|community-acquired'
In addition to ltering for patients between 18-70 years old, the following code was used to exclude other
contraindications based on ICD codes. All resulting descriptors were clinician-reviewed:
CREATE TABLE pna_viral_cohort_exclude AS SELECT DISTINCT d.patientunitstayid
FROM pna_viral_cohort0 AS c
JOIN diagnosis AS d
ON c.patientunitstayid = d.patientunitstayid
WHERE (lower(diagnosisstring) like '%surgery%')
OR (lower(diagnosisstring) like '%neurologic%stroke%')
OR (lower(diagnosisstring) = 'surgery|vascular surgery|surgery-related ischemia|postop
stroke')↪→
OR (lower(diagnosisstring) like '%cranial%hemorrhage%')
OR (lower(diagnosisstring) like '%cancer%')
OR (lower(diagnosisstring) like '%tumor%')
OR (lower(diagnosisstring) like '%lymphoma%')
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OR ((lower(diagnosisstring) like '%hepatic%' OR lower(diagnosisstring) like '%hepatitis%')
AND (diagnosisstring NOT IN ('gastrointestinal|post-GI surgery|s/p hepatic surgery',
'gastrointestinal|hepatic disease|toxic hepatitis',
'infectious diseases|GI infections|intra-abdominal abscess|hepatic|bacterial',
'burns/trauma|trauma - abdomen|hepatic trauma',
'gastrointestinal|abdominal/ general|intra-abdominal abscess|subhepatic',
'gastrointestinal|hepatic disease|hepatorenal syndrome',
'gastrointestinal|hepatic disease|hepatic infarction',
'cardiovascular|shock / hypotension|sepsis|sepsis with single organ dysfunction-acute
hepatic failure',↪→
'toxicology|drug overdose|acetaminophen overdose|hepatic injury expected',
'gastrointestinal|hepatic disease|hepatic dysfunction|pregnancy related',
'gastrointestinal|hepatic disease|hepatic dysfunction',
'gastrointestinal|trauma|hepatic trauma',
'toxicology|drug overdose|acetaminophen overdose|hepatic injury unexpected')))
OR lower(diagnosisstring) like '%liver disease%'
OR lower(diagnosisstring) like '%congestive heart failure%'
OR ((lower(diagnosisstring) like '%renal%')
AND (lower(diagnosisstring) not like '%adrenal%')
AND (icd9code like '40%'));
A.2 MIMIC Cohort
Here is the R code used to extract the MIMIC cohort:
# exclude based in ICD codes
exclusion = bind_rows(
fread(paste0(mimicdir,"DIAGNOSES_ICD.csv")) %>% as_tibble() %>%
inner_join(read_csv(paste0(mimicdir,"D_ICD_DIAGNOSES.csv")) %>%
select(ICD9_CODE,LONG_TITLE), by="ICD9_CODE") %>%
filter(str_detect(str_to_lower(LONG_TITLE),
pattern="isseminated intra|cerebral hem|cerebral inf")) %>%
filter(!str_detect(str_to_lower(LONG_TITLE), pattern="history")),
fread(paste0(mimicdir,"DIAGNOSES_ICD.csv")) %>% as_tibble() %>%
inner_join(read_csv(paste0(mimicdir,"D_ICD_DIAGNOSES.csv")) %>%
select(ICD9_CODE,LONG_TITLE), by="ICD9_CODE") %>%
filter(str_detect(str_to_lower(LONG_TITLE), pattern="urgical")) %>%
filter(!str_detect(str_to_lower(LONG_TITLE), pattern=" not ")) %>%
filter(SEQ_NUM < 3) # only remove if surgery in top 3) %>%
select(SUBJECT_ID) %>% rename(subject_id=SUBJECT_ID) %>% distinct()
exclusion = exclusion %>% bind_rows(
codx %>% # codx.tsv list from MIT-LCP MIMIC extraction code
select(liver_disease, renal_failure,congestive_heart_failure, subject_id) %>%
mutate(anyofthem=liver_disease+renal_failure+congestive_heart_failure) %>%
filter(anyofthem>0) %>%
select(subject_id)) %>% distinct()
# Additional filtering.
# For brevity, the following code only includes the filter operations
# (original code had many joins, mutations, etc. and will released upon publication)
pna_cohort = pna_cohort %>%
filter(as.numeric(age at icu admission)<70) %>%
filter(! hosp_id %in% exclusion$subject_id) %>%
filter(censor_or_deceased_days > 0) %>%
filter(cancer==0)
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B Features and Outcomes
Features and outcomes in eICU were extracted from tables containing patient ICU stays, demographics,
diagnoses, nurse charting, nurse assessments, periodic vitals, laboratory ndings, and treatment informa-
tion. In MIMIC, this data were extracted from tables describing patient demographics, hospital encounters,
ICU encounters, diagnoses, laboratory measurements, nurse charting events, event monitoring, and pro-
cedures.
Features Features were manually merged into their corresponding elements based on a process of visu-
alization, query, and physician review. For example, both eICU and MIMIC store the Glasgow Coma Score
as a Total and as individual Motor, Verbal, and Eye Opening Scores respectively which requires a merge.
The full list of 52 features our model had access to (prior to model selection):
['rbcs', 'wbc', 'platelets', 'hemoglobin', 'hct', 'rdw', 'mcv',
'mch', 'mchc', 'neutrophils', 'lymphocytes', 'monocytes',
'eosinophils', 'basophils', 'bun', 'temperature', 'ph', 'sodium',
'glucose', 'pao2', 'ldh', 'direct_bilirubin', 'total_bilirubin',
'total_protein', 'albumin', 'pt', 'ptt', 'ast', 'alt', 'creatinine',
'troponin', 'alkaline_phosphatase', 'bands', 'bicarbonate', 'calcium',
'chloride', 'potassium', 'age', 'heart_rate', 'sao2', 'gcs',
'respiratory_rate', 'bp_systolic', 'bp_diastolic', 'bp_mean_arterial',
'pleural_effusion', 'orientation', 'African American', 'Asian',
'Caucasian', 'Hispanic', 'Male']
A slightly larger set of features relevant to COVID-19 was initially considered (including smoking, C-
reactive protein, discharge to nursing home), but due to unreliable extraction and high missingness, these
were excluded in both our model’s training and in calculation of existing risk scores.
Outcomes Vasopressor use was dened by use of norepinephrine, epinephrine, phenylephrine, vaso-
pressin, milrinone, dobutamine, or dopamine. Mechanical ventilation was dened by the documentation
of mechanical ventilator use in the treatment table (eICU) or nurse charting (MIMIC).
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C Amount of Missing Data in eICU and MIMIC Cohorts
Table 4 contains the levels of missingness for the variables in Table 1.
Table 4: Levels of missing values in each cohort.
Variable eICU (n = 3617) MIMIC (n = 937)
Age 0.001 (5) 0.0 (0)
Gender 0.001 (5) 0.0 (0)
Pleural eusion 0.0 (0) 0.0 (0)
Orientation 0.334 (1209) 0.48 (450)
Temperature (°C) 0.006 (20) 0.182 (171)
Heart rate (beats per minute) 0.009 (32) 0.018 (17)
Respiratory rate (breaths per minute) 0.001 (3) 0.017 (16)
Systolic blood pressure (mmHg) 0.063 (229) 0.023 (22)
Diastolic blood pressure (mmHg) 0.063 (229) 0.023 (22)
Mean arterial pressure (mmHg) 0.079 (287) 0.018 (17)
Glasgow Coma Scale 0.27 (977) 0.016 (15)
Red blood cells (millions/µL) 0.012 (44) 0.01 (9)
White blood cells (thousands/µL) 0.006 (22) 0.009 (8)
Platelets (thousands/µL) 0.014 (49) 0.01 (9)
Hematocrit (%) 0.006 (23) 0.01 (9)
Red blood cell dist. width (%) 0.057 (207) 0.012 (11)
Mean corpuscular volume (fL) 0.025 (91) 0.011 (10)
Mean corpuscular hemoglobin/ MCH (pg) 0.074 (269) 0.011 (10)
MCH concentration (g/dL) 0.025 (91) 0.01 (9)
Neutrophils (%) 0.24 (869) 0.152 (142)
Lymphocytes (%) 0.167 (603) 0.15 (141)
Monocytes (%) 0.177 (641) 0.152 (142)
Eosinophils (%) 0.209 (755) 0.152 (142)
Basophils (%) 0.256 (925) 0.152 (142)
Band cells (%) 0.752 (2720) 0.454 (425)
Sodium (mmol/L) 0.004 (13) 0.01 (9)
Potassium (mmol/L) 0.008 (29) 0.009 (8)
Chloride (mmol/L) 0.009 (33) 0.009 (8)
Bicarbonate (mmol/L) 0.057 (207) 0.009 (8)
Blood urea nitrogen (mg/dL) 0.004 (14) 0.01 (9)
Creatinine (mg/dL) 0.007 (27) 0.01 (9)
Glucose (mg/dL) 0.006 (23) 0.011 (10)
Aspartate aminotransferase (units/L) 0.174 (628) 0.218 (204)
Alanine aminotransferase (units/L) 0.177 (640) 0.219 (205)
Alkaline phosphatase (units/L) 0.184 (665) 0.223 (209)
C-reactive protein (mg/L) 0.946 (3420) 0.916 (858)
Direct bilirubin (mg/L) 0.808 (2923) 0.82 (768)
Total bilirubin (mg/L) 0.185 (670) 0.227 (213)
Total protein (g/dL) 0.184 (664) 0.841 (788)
Calcium (mg/dL) 0.021 (77) 0.027 (25)
Albumin (g/dL) 0.16 (577) 0.279 (261)
Troponin (ng/mL) 0.591 (2138) 0.505 (473)
Prothrombin time (sec) 0.396 (1431) 0.035 (33)
Partial thromboplastin time (sec) 0.545 (1973) 0.038 (36)
pH 0.244 (883) 0.104 (97)
Partial pressure of oxygen (mmHg) 0.223 (807) 0.134 (126)
Arterial oxygen saturation (mmHg) 0.015 (54) 0.726 (680)
Deceased 0.0 (0) 0.0 (0)
Vasopressors administered 0.0 (0) 0.0 (0)
Ventilator used 0.0 (0) 0.0 (0)
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D Grid Search Values for λ
The grid search values for λ: [0.5, 0.375, 0.25, 0.125, 0.10, 0.075, 0.05, 0.0225, 0.025, 0.0275, 0.02, 0.0175, 0.015,
0.0125, 0.01, 0.005, 0.0005]. Also, Figure F.2 shows the tradeo between concordance versus the number of
features selected with dierent λ.
E Nonzero Coecients in the Model
Figure E.1 is a boxplot of the coecients of the model learned on the normalized data.
Figure E.1: Coecients of the learned Cox model with penalty 0.01 and L1 regularization, with 95% con-
dence intervals (equivalent to what is reported in Table 2).
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For reference, the means and standard deviations of the nonzero features are in Table 5.
Table 5: Mean and standard deviation of nonzero Lasso-COX features.
Feature mean std. dev.
wbc 12.9 8.91
platelets 208 108
rdw 15.8 2.47
neutrophils 79.1 13
bun 25.1 19.5
ph 7.38 0.0713
direct_bilirubin 0.385 0.816
albumin 2.65 0.636
pt 16.6 6.75
ast 143 774
troponin 1.07 3.85
age 54.4 12.5
heart_rate 89.4 17.8
sao2 95.8 4.12
gcs 11.3 3.26
bp_systolic 122 22
bp_diastolic 67.7 15.1
bp_mean_arterial 83.7 17.9
F Sensitivity to MissForest Imputation
MissForest [Stekhoven and BÃĳhlmann, 2011] is a non-parametric missing value imputation technique
which iteratively ts random forests to impute missing values in each column, starting with the column
with the fewest missing values. The process repeats itself until the dierence between imputed arrays over
successive iterations meets a stopping criterion. Our experiments use the missingpy package to perform
MissForest imputation.
To check the sensitivity of model selection to MissForest imputation, we re-ran the imputation algo-
rithm with 10 dierent seeds and re-ran grid search to nd the best set of parameters on each of these
10 datasets. As discussed in the paper, Lasso-Cox with a penalty (λ) level of 0.01 consistently achieved
high concordance (around 0.73) while only selecting approximately 18 same features out of a total of 52
features across the 10 dierent seeds. Selecting additional features by lowering the penalty level did not
yield substantial gains in performance (Figure F.1).
With a penalty level of 0.01, Lasso-Cox was consistent in the features selected and coecients it
learned. Figure F.2 shows that across all except one of the ten random forest imputations of the dataset (in
which it selected one less feature), all 18 features were selected and the model learned relatively consistent
coecients.
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Figure F.1: Tradeo from controlling the penalty hyperparameter λ in Lasso-Cox. As λ decreases, more
features are selected and concordance increases. Beyond λ = 0.01, the gain in performance levels o.
Figure F.2: Coecients learned by the L1-regularized cox model with penalty 0.01 from ten random forest
imputations of the data. The x-axis has the variable name (number of times that the variable has nonzero
coecient across 10 runs)
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G Survival Curves for High and Low Risk Groups
Figure G.1 contains survival curves for high and low risk groups derived from the PEER score (our model),
CURB-65, PSI/PORT, SMART-COP, and GOQ. The high/low risk groups for CURB-65 and PSI/PORT were
created by following the criteria listed in their respective papers where former one to greater or equal to
3 and the later one to higher or equal to 130. For SMART-COP and GOQ, since we did not nd a cuto
criterion in their papers, we just follow our criterion to set the cuto point as the 90th percentitle of the
train set risk.
       PEER        
Figure G.1: Comparison of survival curves corresponding to risk strata derived from the PEER score, CURB-
65, PSI/PORT, SMART-COP, and GOQ
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